循环肿瘤DNA
微小残留病
液体活检
肺癌
医学
癌症
肿瘤科
癌症的体细胞进化
内科学
癌症研究
计算生物学
骨髓
生物
作者
Bruna Pellini,Jeffrey J. Szymanski,R Chin,Paul A. Jones,Aadel A. Chaudhuri
标识
DOI:10.1016/j.thorsurg.2020.01.005
摘要
Liquid biopsies for the diagnosis and treatment of lung cancer have developed rapidly, driven primarily by technical advances in sensitivity to detect circulating tumor DNA (ctDNA). Still, technical limitations such as the challenge of detecting low-level ctDNA variants and distinguishing tumor-related variants from clonal hematopoiesis remain. With further technical advancements, new applications for ctDNA analysis are emerging including detection of post-treatment molecular residual disease (MRD), clinical trial selection, and early cancer detection. This chapter reviews the current state of ctDNA testing in NSCLC, the underlying technological advances enabling ctDNA detection, and the potential to expand ctDNA analysis to new applications.
科研通智能强力驱动
Strongly Powered by AbleSci AI